title: [Clinical analysis of 13 patients with primary bone lymphoma].
abstract: OBJECTIVE
  To analyse the clinical featuers, prognositic factors and treatment outcomes of primary bone lymphoma(PBL).
  
  
  METHODS
  The clinical data of 13 patients with PBL in our hospital from 2005 to 2014 were analysed retrospectively.
  
  
  RESULTS
  The median age of these patients was 40 (25-71) years old, ostealgia was the initial symptom(100%). The main histologic type was diffuse large B cell lymphoma (DLBCL) (11/13, 84.6%), and among other 2 cases 1 case was anaplastic large cell lymphoma(ALCL) and other 1 case was B lymphoblastic lymphoma. All 13 cases were treated with chemotherapy, 6 cases got complete remission(46.2%) and 7 cases got partial remission(53.8%). There was no statistical relation of age, sex, stage, β2-MG level, LDH level, pathological type and the application of rituximab with the complete remission rate (P>0.05). After the median follow up of 12 (3-72) months, 3 cases died of diease progression and 6 cases maintained in complete remission, the median progression-free survival was 13 (2-72) months.
  
  
  CONCLUSIONS
  The most common histologic type is DLBCL, its main treatment method is the combined chemical therapy, but the role of rituximab in treatment is not clear, thus larger clinical trial is necessary.
authors.affiliation: Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Dong
authors.affiliation: Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: Yu-Ping
authors.initials: YP
authors.lastname: Chen
authors.affiliation: Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: Ji-Jun
authors.initials: JJ
authors.lastname: Wang
authors.affiliation: Department of Hematology, Peking University Third Hospital, Beijing 100191, China. E-mail: jinghm@yahoo.com.
authors.forename: Hong-Mei
authors.initials: HM
authors.lastname: Jing
authors.affiliation: Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Ke
mesh_terms: D000328:Adult; D000368:Aged; D001859:Bone Neoplasms; D018572:Disease-Free Survival; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome